Trigeminal NeuralgiaNCT06779578
Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia
A study testing Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency in people with Trigeminal Neuralgia and Refractory Pain, run by Alexandria University at 2 sites in Egypt.
Trial summary
A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Trigeminal Neuralgia, Refractory Pain
- What is being tested?
- Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 2 sitesEgypt
- Study dates
- 1 Jan 2024to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.
- Patients with idiopathic TN, with symptomatic clinical topography of V2 and/or V3.
- Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.
- Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5/10 after monotherapy or polytherapy in appropriate medical doses.
Who cannot join
- Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Trigeminal neuralgia with V1 symptomatic clinical topography.
- Trigeminal neuralgia comorbid with other atypical facial pain disorders.
- Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.
- Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.
- Patients who refused to participate in the study.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt2 sites, 2 recruiting
- Recruiting
Alexandria University Faculty of Medicine
Alexandria, 21517
Eman Hamdy, PhD
- Recruiting
Cairo University Kasr Alainy Faculty of Medicine
Cairo
Ahmed Elshal, PhD
About this study
Official title: The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study
A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.
Read the detailed description
This will be a prospective exploratory that will be conducted on patients with the inclusion and exclusion criteria detailed.
At the baseline visit, the sociodemographic data (age, sex, smoking status) and clinical data (TN etiology (idiopathic or symptomatic), TN phenotype (purely paroxysmal or with concomitant continuous pain), clinical symptoms topography (V2, V3), brain MRI findings, previous medications and interventions, and comorbidities) will be collected. The patients will be randomly assigned to undergo bipolar PRF or monopolar PRF using a simple randomization technique.
Pain scores will be assessed using the nominal rating scale (NRS) at baseline, within two weeks postoperatively, and at 1-month, 3-month, and 6-month intervals. Patient satisfaction will be assessed within two weeks following the intervention on a five-point Likert scale (5 represents very good and 1 means very bad). Treatment success will be defined as at least a 50% reduction in pain scores. The duration to pain control and the duration to pain recurrence/rebound will be assessed at follow-up visits. The patient's postoperative need for medications or further pain interventions will be detailed. Intraoperative and postinterventional complications will be monitored and documented.
Study interventions For the PRF procedure, all patients will be prepared in the operating room and will undergo standard operative monitoring (i.e., blood pressure, electrocardiography, and pulse oximetry). They will be positioned in a supine position with slight neck extension. Sedation will be provided (100 Ig fentanyl and 2 mg midazolam intravenously). Skin preparation will be performed using chlorhexidine.
I- Monopolar PRF In the monopolar PRF, an RF cannula (22-gauge, 100 mm, with a 10 mm active tip (SMK)) will be percutaneously advanced at the posterior border of the foramen ovale under fluoroscopic guidance. For confirming the detection of the mandibular nerve, sensory stimulation will be performed via the radiofrequency generator at a current of 0.5 to 1 V at a frequency of 50 Hz to elicit paresthesia response in the mandibular region. Motor stimulation will be performed via the generator at a current of 1 - 2 V applied at a frequency of 2 Hz to obtain a contraction response at the masseter muscle. After obtaining the appropriate responses, PRF will be applied at a fixed heat energy of 42 °C for a period of 240 seconds10.
II- Bipolar PRF For bipolar PRF, two RF cannulas will be advanced in the foramen ovale under fluoroscopic guidance. The first (22-gauge, 100 mm, and 10-mm active tip (SMK)) will be placed at the anterior border of the foramen ovale, and then the second (same parameters) will be advanced at the posterior border. The correct position will be confirmed on the lateral position until the correct placement at V2. Sensory and motor testing will be performed as aforementioned in the monopolar PRF to confirm the appropriate capture of the trigeminal nerve. Following obtaining the appropriate responses, PRF will be performed in two cycles, three minutes each, at a temperature of 42ºC and a current of 85 V and a 20-millisecond pulse width13.
- Conditions
- Trigeminal Neuralgia, Refractory Pain
- Being tested
- Bipolar pulsed radiofrequency, Mopolar pulsed radiofrequency
- Keywords
- trigeminal neuralgia, Radiofrequency ablation, Pulsed radiofrequency, Monopolar pulsed radiofrequency, Bipolar pulsed radiofrequnency
- Medical subject headings
- Trigeminal Neuralgia, Pain, Intractable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bipolar pulsed radiofrequencyProcedure or surgery
Bipolar pulsed radiofrequency ablation: the active comparator
Mopolar pulsed radiofrequencyProcedure or surgery
Monopolar pulsed radiofrequency ablation: the placebo
| Study group | Role | What they receive |
|---|---|---|
| Monopolar pulsed radiofrequncy | Placebo comparator | Patients with refractory TN undergoing monopolar pulsed radiofrequency Receives: Procedure: Mopolar pulsed radiofrequency |
| Bipolar pulsed radiofrequency | Active comparator | Patients with refractory TN undergoing bipolar pulsed radiofrequency Receives: Procedure: Bipolar pulsed radiofrequency |
What is being measured
The primary outcome is the main question the study is designed to answer.
Numerical pain scale (NRS)
50% Pain reduction in the numerical rating scale (NRS)
Measured: Two weeks, 1 month, 3 months, and 6 months
Secondary outcomes (1)
Adverse events monitoring (Frequency, severity, seriousness, and causality)
Frequency, type, and severity of adverse events. Classification of AEs as mild, moderate, or severe. Assessment of causality between the treatment and the AE
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2025
- Study start1 Jan 2024
- Primary completion1 Jun 2025 (estimated)
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Trigeminal NeuralgiaStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Explaratory
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eman Hamdy, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06779578
- Sponsor's protocol ID
- 0307084
- Status last verified
- Jan 2025
- First submitted
- 13 Jan 2025
- Last updated
- 17 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study
- ClinicalTrials.gov ID
- NCT06779578
- Acronym / sponsor ID
- 0307084
- Conditions
- Trigeminal Neuralgia, Refractory Pain
- Keywords
- trigeminal neuralgia, Radiofrequency ablation, Pulsed radiofrequency, Monopolar pulsed radiofrequency, Bipolar pulsed radiofrequnency
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 1 Jun 2025 (estimated)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 16 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.
Detailed description
This will be a prospective exploratory that will be conducted on patients with the inclusion and exclusion criteria detailed.
At the baseline visit, the sociodemographic data (age, sex, smoking status) and clinical data (TN etiology (idiopathic or symptomatic), TN phenotype (purely paroxysmal or with concomitant continuous pain), clinical symptoms topography (V2, V3), brain MRI findings, previous medications and interventions, and comorbidities) will be collected. The patients will be randomly assigned to undergo bipolar PRF or monopolar PRF using a simple randomization technique.
Pain scores will be assessed using the nominal rating scale (NRS) at baseline, within two weeks postoperatively, and at 1-month, 3-month, and 6-month intervals. Patient satisfaction will be assessed within two weeks following the intervention on a five-point Likert scale (5 represents very good and 1 means very bad). Treatment success will be defined as at least a 50% reduction in pain scores. The duration to pain control and the duration to pain recurrence/rebound will be assessed at follow-up visits. The patient's postoperative need for medications or further pain interventions will be detailed. Intraoperative and postinterventional complications will be monitored and documented.
Study interventions For the PRF procedure, all patients will be prepared in the operating room and will undergo standard operative monitoring (i.e., blood pressure, electrocardiography, and pulse oximetry). They will be positioned in a supine position with slight neck extension. Sedation will be provided (100 Ig fentanyl and 2 mg midazolam intravenously). Skin preparation will be performed using chlorhexidine.
I- Monopolar PRF In the monopolar PRF, an RF cannula (22-gauge, 100 mm, with a 10 mm active tip (SMK)) will be percutaneously advanced at the posterior border of the foramen ovale under fluoroscopic guidance. For confirming the detection of the mandibular nerve, sensory stimulation will be performed via the radiofrequency generator at a current of 0.5 to 1 V at a frequency of 50 Hz to elicit paresthesia response in the mandibular region. Motor stimulation will be performed via the generator at a current of 1 - 2 V applied at a frequency of 2 Hz to obtain a contraction response at the masseter muscle. After obtaining the appropriate responses, PRF will be applied at a fixed heat energy of 42 °C for a period of 240 seconds10.
II- Bipolar PRF For bipolar PRF, two RF cannulas will be advanced in the foramen ovale under fluoroscopic guidance. The first (22-gauge, 100 mm, and 10-mm active tip (SMK)) will be placed at the anterior border of the foramen ovale, and then the second (same parameters) will be advanced at the posterior border. The correct position will be confirmed on the lateral position until the correct placement at V2. Sensory and motor testing will be performed as aforementioned in the monopolar PRF to confirm the appropriate capture of the trigeminal nerve. Following obtaining the appropriate responses, PRF will be performed in two cycles, three minutes each, at a temperature of 42ºC and a current of 85 V and a 20-millisecond pulse width13.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Explaratory
| Arm | Type | Receives |
|---|---|---|
| Monopolar pulsed radiofrequncy | Placebo comparator | Procedure: Mopolar pulsed radiofrequencyPatients with refractory TN undergoing monopolar pulsed radiofrequency |
| Bipolar pulsed radiofrequency | Active comparator | Procedure: Bipolar pulsed radiofrequencyPatients with refractory TN undergoing bipolar pulsed radiofrequency |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.
- Patients with idiopathic TN, with symptomatic clinical topography of V2 and/or V3.
- Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.
- Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5/10 after monotherapy or polytherapy in appropriate medical doses.
Key exclusion criteria (6 listed)
- Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Trigeminal neuralgia with V1 symptomatic clinical topography.
- Trigeminal neuralgia comorbid with other atypical facial pain disorders.
- Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.
- Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bipolar pulsed radiofrequencyBipolar pulsed radiofrequency ablation: the active comparator | Procedure or surgery | Bipolar pulsed radiofrequency |
| Mopolar pulsed radiofrequencyMonopolar pulsed radiofrequency ablation: the placebo | Procedure or surgery | Monopolar pulsed radiofrequncy |
Primary outcome
Numerical pain scale (NRS)
Time frame: Two weeks, 1 month, 3 months, and 6 months
50% Pain reduction in the numerical rating scale (NRS)
1 secondary outcome
Adverse events monitoring (Frequency, severity, seriousness, and causality)
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Trigeminal Neuralgia
RecruitingPhase 2
Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study
Cancer Pain, Orofacial Pain
RecruitingObservational study
Trigeminal Neuralgia Electrophysiology
Trigeminal Neuralgia
RecruitingEarly Phase 1
Trigeminal Evoked Responses to Improve Rhizotomy
Trigeminal Neuralgia, Rhizotomy
Not yet recruitingObservational study
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
Malignant Tumor, Benign Neoplasm
RecruitingPhase 1/2
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
Trigeminal Neuralgia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency in people with Trigeminal Neuralgia and Refractory Pain, run by Alexandria University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eman Hamdy, PhD (+201061402092, eman.ameen@alexmed.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Numerical pain scale (NRS) (time frame: Two weeks, 1 month, 3 months, and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.